EUVIMEDEUVIMED entdecken
Crossref

A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer

Xiaomei Gao, Yongxiang Tang, Minfeng Chen, Jian Li, Hongling Yin, Yu Gan, Xiongbin Zu, Yi Cai iD, Shuo Hu

European Journal of Nuclear Medicine and Molecular Imaging · 2023-06 · 50 (7) · 2177-2187

DOI: 10.1007/s00259-023-06142-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 22.02.2023. Verfasst von Xiaomei Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hosp…. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Science and Technology Innovation Program of Hunan Province, the Key Research and Development Program of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Prostate-specific membrane antigen (PSMA)-based PET/CT imaging has limitations in the diagnosis of prostate cancer (PCa). We recruited 207 participants with suspicious PCa to perform PET/CT imaging with radiolabeled gastrin-releasing peptide receptor (GRPR) antagonist, [68Ga]Ga-RM26, and compare with [68Ga]Ga-PSMA-617 and histopathology. METHODS: Every participant with suspicious PCa was scanned with both [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT. PET/CT imaging was compared using pathologic specimens as a reference standard. RESULTS: Of the 207 participants analyzed, 125 had cancer, and 82 were diagnosed with benign prostatic hyperplasia (BPH). The sensitivity and specificity of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging differed significantly for detecting clinically significant PCa. The area under the ROC curve (AUC) was 0.54 for [68Ga]Ga-RM26 PET/CT and 0.91 for [68Ga]Ga-PSMA-617 PET/CT in detecting PCa. For clinically significant PCa imaging, the AUCs were 0.51 vs. 0.93, respectively. [68Ga]Ga-RM26 PET/CT imaging had higher sensitivity for PCa with Gleason score (GS) = 6 (p = 0.03) than [68Ga]Ga-PSMA-617 PET/CT but poor specificity (20.73%). In the group with PSA < 10 ng/mL, the sensitivity, specificity, and AUC of [68Ga]Ga-RM26 PET/CT were lower than [68Ga]Ga-PSMA-617 PET/CT (60.00% vs. 80.30%, p = 0.12, 23.26% vs. 88.37%, p = 0.000, and 0.524 vs. 0.822, p = 0.000, respectively). [68Ga]Ga-RM26 PET/CT exhibited significantly higher SUVmax in specimens with GS = 6 (p = 0.04) and in the low-risk group (p = 0.01), and its uptake did not increase with PSA level, GS, or clinical stage. CONCLUSION: This prospective study provided evidence for the superior accuracy of [68Ga]Ga-PSMA-617 PET/CT over [68Ga]Ga-RM26 PET/CT in detecting more clinically significant PCa. [68Ga]Ga-RM26 PET/CT showed an advantage for imaging low-risk PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansPositron Emission Tomography Computed TomographyProspective StudiesGallium RadioisotopesDipeptidesHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

DiagnosisHistopathologyProstate cancer[68Ga]Ga-PSMA-617 PET/CT[68Ga]Ga-RM26 PET/CT

Substanzen

Prostate-Specific AntigenGallium RadioisotopesPSMA-617DipeptidesHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya Road, Ch…
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya R…
  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya Road, Chan…
  • Key Laboratory of Biological, Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya Road, Changsha City, 410008, People's Republic of China. hushuo2018@1…

ORCID-Profile: Yi Cai

Förderung

  • National Natural Science Foundation of China
  • the Science and Technology Innovation Program of Hunan Province
  • the Key Research and Development Program of Hunan Province
  • Natural Science Foundation of Hunan Province
  • the Clinical Research Fund Project of National Geriatric Disease Clinical Research Center

Zitieren

APA

Gao, X., Tang, Y., Chen, M., Li, J., Yin, H., Gan, Y., Zu, X., Cai, Y., & Hu, S. (2023). A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 2177-2187. https://doi.org/10.1007/s00259-023-06142-2

Vancouver

Gao X, Tang Y, Chen M, Li J, Yin H, Gan Y, et al. A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(7):2177-2187. doi:10.1007/s00259-023-06142-2

BibTeX
@article{Gao2023,
  author = {Gao, Xiaomei and Tang, Yongxiang and Chen, Minfeng and Li, Jian and Yin, Hongling and Gan, Yu and Zu, Xiongbin and Cai, Yi and Hu, Shuo},
  title = {A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  volume = {50},
  number = {7},
  pages = {2177--2187},
  doi = {10.1007/s00259-023-06142-2}
}
Kostenlos starten →